CLCN2: A Potential Drug Target and Biomarker (G1181)

Target Name: CLCN2

NCBI ID: G1181

CLCN2

CLCN2: A Potential Drug Target and Biomarker

CLCN2 (Clotting Factor II) is a protein that is expressed in various tissues and cells in the body. It plays a critical role in blood clotting and has been implicated in a number of diseases, including heart disease, cancer, and neurological disorders. In recent years, researchers have been investigating the potential uses of CLCN2 as a drug target and biomarker.

The blood clotting system is a complex process that involves the recruitment of clotting factors to the site of a blood vessel damage or injury. Clotting factors are proteins that are produced by the body to help form blood clots and stop bleeding. CLCN2 is one of the most well-studied clotting factors, and its function in the body has been extensively investigated.

In addition to its role in blood clotting, CLCN2 has also been shown to play a number of other roles in the body. For example, it has been shown to regulate the growth and differentiation of cells, and it has been implicated in the development and progression of a number of diseases, including cancer.

As a result of its widespread involvement in various bodily processes, CLCN2 has become a focus of interest for researchers as a potential drug target. By targeting CLCN2 with small molecules or other compounds, researchers hope to develop new treatments for a variety of diseases.

One approach to targeting CLCN2 is through the use of small molecules, such as those that mimic the activity of natural CLCN2. These molecules can be designed to interact with specific CLCN2-binding sites, leading to the formation of CLCN2-containing clots or other cellular structures. By blocking the activity of CLCN2, researchers hope to prevent blood clots from forming and reduce the risk of cardiovascular disease.

Another approach to targeting CLCN2 is through the use of antibodies, which are proteins that recognize and bind to specific molecules in the body. Researchers have developed antibodies that are designed to recognize and bind to CLCN2, with the goal of using these antibodies to block the activity of CLCN2 and prevent blood clots from forming.

In addition to its potential as a drug target, CLCN2 has also been shown to be a potential biomarker for a number of diseases. For example, CLCN2 has been shown to be elevated in the blood of people with heart disease, and it has been used as a biomarker to predict the risk of heart failure in patients with heart disease.

Research into CLCN2 has also led to a better understanding of its role in the development and progression of cancer. For example, studies have shown that CLCN2 is often expressed in various types of cancer, and that it plays a role in the development of cancer stem cells.

Overall, CLCN2 is a protein that has the potential to be a valuable drug target and biomarker. As research continues to evolve, it is likely that the role of CLCN2 in various diseases will continue to be explored and understood.

Protein Name: Chloride Voltage-gated Channel 2

Functions: Voltage-gated chloride channel. Chloride channels have several functions including the regulation of cell volume, membrane potential stabilization, signal transduction and transepithelial transport. Involved in the regulation of aldosterone production. The opening of CLCN2 channels at hyperpolarized membrane potentials in the glomerulosa causes cell membrane depolarization, activation of voltage-gated Ca2+ channels and increased expression of aldosterone synthase, the rate-limiting enzyme for aldosterone biosynthesis (PubMed:29403011, PubMed:29403012)

The "CLCN2 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CLCN2 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets